TARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and its collaborator Bayer today announced that aflibercept 8 mg and EYLEA® (aflibercept) Injection ...

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...

In this video from the American Academy of Ophthalmology meeting, Diana V. Do, MD, discusses the real-world use of aflibercept 8 mg in wet age-related macular degeneration or diabetic macular edema.

Regeneron Pharmaceuticals Inc REGN announced the first presentation of two-year (96 weeks) results from the pivotal PHOTON trial of aflibercept 8 mg with 12- and 16-week dosing regimens, compared to ...

If approved, extended regimen would provide a longer treatment interval and additional dosing flexibility, alongside approved every 4- and 8-week dosing regimens TARRYTOWN, N.Y., June 29, 2022 ...

SEATTLE — The number of initial monthly aflibercept injections may play a role in achieving optimal visual outcomes in diabetic macular edema, according to a study presented at the American Society of ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated ...